Introduction
Cagrilintide and Semaglutide target different hormonal pathways involved in appetite regulation and metabolic control. Semaglutide is the established GLP-1 receptor agonist, while cagrilintide is a long-acting amylin analog that mimics the satiety hormone co-secreted with insulin from pancreatic beta cells. Novo Nordisk's combination of both (CagriSema) aims to achieve weight loss exceeding either agent alone by targeting two complementary central appetite-suppression pathways.
Mechanism of Action Comparison
Semaglutide activates GLP-1 receptors in the hypothalamus (arcuate nucleus, area postrema) to suppress appetite, enhance insulin secretion, and delay gastric emptying. Its mechanism is well-characterized after a decade of clinical use, producing ~15-17% weight loss as monotherapy.
Cagrilintide is an acylated long-acting analog of amylin (islet amyloid polypeptide), a 37-amino acid peptide co-secreted with insulin that promotes satiety through calcitonin receptor (CTR) and amylin receptor (AMY1/AMY3) activation in the area postrema and lateral parabrachial nucleus. Amylin slows gastric emptying, suppresses postprandial glucagon, and reduces meal size through distinct neural circuits from GLP-1[1].
Key Differences
| Feature | Cagrilintide | Semaglutide |
|---|---|---|
| Receptor Target | Amylin/calcitonin receptors | GLP-1 receptor |
| Endogenous Hormone | Amylin (IAPP) | GLP-1 |
| Satiety Pathway | Area postrema, parabrachial nucleus | Arcuate nucleus, area postrema |
| Monotherapy Weight Loss | ~10-11% (Phase 2) | ~15-17% (Phase 3) |
| Combination (CagriSema) | ~25% weight loss in Phase 3 trials | |
| Dosing Frequency | Once weekly (SC) | Once weekly (SC) |
Research Applications
Semaglutide is the benchmark for GLP-1 pathway research with broad clinical applications. Cagrilintide is studied in amylin biology, dual-pathway appetite suppression, and beta-cell physiology research. The CagriSema combination program is one of the most anticipated obesity trials, testing whether complementary amylin + GLP-1 agonism can match or exceed triple agonist (Retatrutide) weight loss results through a different mechanistic approach.
Which to Choose for Your Research?
For GLP-1-specific research, semaglutide is the established standard. For amylin pathway investigation or studies on beta-cell co-secretion biology, cagrilintide provides a targeted tool. For maximum efficacy research, the combination approach mirrors the CagriSema clinical program. Researchers comparing multi-target strategies can evaluate CagriSema (GLP-1 + amylin) against Tirzepatide (GLP-1 + GIP) and retatrutide (GLP-1 + GIP + glucagon).
